Our approach to screening drugs is very different from that currently used by the pharmaceutical companies. AD is a complex disease associated with old age, and our goal is to make drugs like J147 that reduce the multiple toxicities associated with the disease, not just one. We believe J147 is the best AD drug candidate in the pipeline and will be effective if we can get it into the clinic.In contrast to the Salk Lab's multifaceted approach, Big Pharma's research on Alzheimer's (and other) drugs focuses instead on one molecular disease-related target. Success has been limited. For example, Big Pharma's focus on amyloid beta proteins as an Alzheimer's target has repeatedly failed to provide useful drugs. While amyloid beta plays some role in the disease, Schubert says, it's far from the whole story.
Big Pharma hasn't had much success with its approach, but it has the money to keep repeating its flawed research model. And it continues to refuse funding trials on new and promising drug candidates based on natural substances.